



Dextenza® (dexamethasone) – Expanded indication

- On June 21, 2019, [Ocular Therapeutix announced](#) the FDA approval of [Dextenza \(dexamethasone\)](#), for the treatment of ocular inflammation and pain following ophthalmic surgery.
 - Previously, Dextenza was only approved for the treatment of ocular pain following ophthalmic surgery.
- The expanded indication was approved based on data from three double-blind studies of 926 patients who received Dextenza or vehicle after cataract surgery.
 - In two of the three studies, Dextenza had a statistically significantly higher proportion of patients vs. the vehicle group who had an absence of anterior chamber cells on post-operative day 14.
- Dextenza is an ophthalmic insert that is inserted in the lower lacrimal punctum into the canaliculus. A single Dextenza insert releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.